丹红注射液治疗缺血性中风急性期临床疗效的系统评价

摘要

目的 系统评价丹红注射液治疗缺血性中风急性期的临床疗效及安全性.方法 收集丹红注射液治疗缺血性中风急性期随机对照试验文献,筛选合格研究,应用Jadad评分法进行质量评价,运用异质性检验、Meta分析、敏感性分析等方法统计相关数据.结果 14项研究符合纳入标准,Meta分析结果显示,总有效率比较的合并RR(99％CI)为1.22(1.14,1.31)；神经功能缺损程度评分比较的WMD(99％CI)为-4.59(-6.84,-2.35),需治疗的病例数(99％CI)为5.88(4.55,9.09).结论 统计结果提示丹红注射液有益于改善缺血性中风急性期神经功能缺损状况,且安全性较好.纳入研究质量较低、潜在的临床异质性、统计结果稳定性较弱、待评价研究等因素在一定程度上降低了上述统计结果的可靠性.%Objective: To evaluate efficacy and safety of Donhong Injection for acute cerebral ischemic stroke and the safety of this treatment. Methods: Randomized controlled trails (RCTs) of Danhong Injection Treatment for acute cerebral ischemic stroke were identified.Eligible studies were included.The methodological quality of inclusive trails was assessed by jaded scale. Hetetogeneity test,Meta-analysis,sensitivity analysis were used to analyse data. Results: 4 RCTs were included. Meta-analysis indicated that relative risk of overall effective rate was 1.22[99%CI(1.14,1.31)],WMD(99%CI) of neural function defect score was -4.59(-6.84,-2.35),number needed to treat was5.88 [99%CI(4.55,9.09)]. Conclusion: Statistical results suggest that Danhong injection can improve ischemic stroke acute phase nerve function defect condition,and safety is better, the factors,such as lower quality of the Included research,potential clinical heterogeneity,the weak statistical results stability and reduce the statistical results of reliability in a certain extent.